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Abstract
APOBEC4 (A4) is a member of the AID/APOBEC family of cytidine deaminases. In this
study we found a high mRNA expression of A4 in human testis. In contrast, there were only
low levels of A4 mRNA detectable in 293T, HeLa, Jurkat or A3.01 cells. Ectopic expression
of A4 in HeLa cells resulted in mostly cytoplasmic localization of the protein. To test whether
A4 has antiviral activity similar to that of proteins of the APOBEC3 (A3) subfamily, A4 was
co-expressed in 293T cells with wild type HIV-1 and HIV-1 luciferase reporter viruses. We
found that A4 did not inhibit the replication of HIV-1 but instead enhanced the production of
HIV-1 in a dose-dependent manner and seemed to act on the viral LTR. A4 did not show
detectable cytidine deamination activity in vitro and weakly interacted with single-stranded
DNA. The presence of A4 in virus producer cells enhanced HIV-1 replication by transiently
transfected A4 or stably expressed A4 in HIV-susceptible cells. APOBEC4 was capable of
similarly enhancing transcription from a broad spectrum of promoters, regardless of whether
they were viral or mammalian. We hypothesize that A4 may have a natural role in modulat-
ing host promoters or endogenous LTR promoters.
Introduction
The AID/APOBEC (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like) poly-
nucleotide (deoxy) cytidine deaminases family consists of AICDA (activation-induced cytidine
deaminase, AID), APOBEC1 (A1), APOBEC2 (A2), APOBEC3 (A3), which has the following
seven paralogues in humans: A3A–A3D, A3F–A3H, and APOBEC4 (A4) [1–5]. These enzymes
have a diverse range of functions and substrate specificities. Cytidine deamination of single-
stranded DNA or RNA was shown to be the principal activity of the AID, A1, and A3 proteins in
biochemical and cell culture assays, but such evidence is lacking for A2 and A4 proteins.
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Cytidine deaminases of the A3 gene family can inhibit long terminal repeat (LTR)—and
non-LTR-retrotransposons and have broad antiviral activity against retroviruses such as HIV
and murine leukemia virus (MLV), hepadnaviruses, and non-related viruses [6–21]. A3s
mainly act by deaminating cytidine into uridine using single-stranded DNA as a substrate (for
review, see [22]). DNA editing introduces hypermutations of the viral genome that eventually
render the target genome inactive. Conversely, retroviruses have evolved countermeasures to
prevent encapsidation of A3s into viral particles. For example, the Vif protein in lentiviruses,
the Bet protein in foamyviruses, the glycosylated Gag (glyco-Gag) protein in MLV, and the
nucleocapsid protein in Human T-cell lymphotropic virus accomplish this counteraction using
different mechanisms [17, 19, 20, 22–28].
AID is a B lymphoid protein that deaminates chromosomal DNA, thereby inducing somatic
hypermutations and gene conversion. Furthermore, AID stimulates class switch recombination
in B cells [29–35]. AID can restrict LINE-1 (L1) retrotransposition [15, 36, 37], but it is inactive
against HIV-1 [38–40]. A1 catalyzes the cytidine-to-uridine editing of apolipoprotein B mRNA
in the intestine [41, 42]. Editing generates a premature stop codon, which is translated to pro-
duce a truncated form of apolipoprotein B protein, termed apoB48, that has distinct functions
in lipid transport [43]. The editing mechanism is highly specific for residue C6666 and works
in conjunction with A1 complementation factor [44]. Other mRNA targets for A1 editing were
recently identified [45]. A1s of rabbit and rodents inhibit both MLV and HIV-1 by mutating
the viral RNA and DNA; in contrast human A1 does not edit in vitro [39, 46–49]. In addition,
L1 retrotransposons can be restricted by A1s derived from rodents and rabbits, but this effect is
weak for human A1 [15, 50]. A2 plays an important role in regulating and maintaining muscle
development in mammals [51]. A2 did not exhibit cytidine deaminase activity of DNA sub-
strates in bacterial or yeast mutation assays [52, 53]. Human A2 lacks inhibitory activity against
retrotransposons [9, 54, 55] and HIV-1 [38, 40], and murine A2 does not inhibit or edit MLV
[46].
A4 protein is more closely related to A1 than to the other APOBECs, and the A4 gene is
conserved in chimpanzee, rhesus monkey, dog, cow, mouse, rat, chicken, and frog [3]. A4 is
considered to be a putative cytidine-to-uridine editing enzyme. However, experiments con-
ducted using A4 overexpression in yeast and bacteria failed to show cytidine deamination
activity in DNA [52]. In mice, the A4 gene is expressed primarily in testis [3], which suggests
that it may be involved in spermatogenesis. Whether human A4 participates in intrinsic immu-
nity against HIV as demonstrated for A3s and A1 is unknown, but these anti-viral activities of
its sister proteins suggest that it might be possible. Therefore we set out to evaluate the effect of
human A4 on the replication of HIV-1 in vitro.
Results
Analysis of A4 expression in cell lines and human testis tissue
Based on information of public repositories (e.g. GenBank) A4 is detectable mainly in human
testis, and neither full length A4 mRNAs nor expressed sequence tags (ESTs) have been identi-
fied in blood cells, lymphoid tissues, T cells or macrophages. To functionally test A4 in cell cul-
ture, we first wanted to determine whether widely used human cell lines express A4. To this
end, semi-quantitative RT PCRs on total RNA from the 293T, HeLa, A3.01 T, and Jurkat T cell
lines were conducted and the weakly detected PCR products were cloned and sequence verified
(Fig 1A). We further compared the A4 expression levels of these cell lines to A4 expression in
human testis tissue by quantitative real-time RT PCR on total RNA. Data demonstrate that A4
expression levels in testis are approximately 30- to 50-fold higher than those in the tested cell
lines (Fig 1B). A4 expression plasmids were generated with either N-terminal or C-terminal
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HA-tags or without any tag (HA-A4, A4-HA, A4, Fig 2A). A4 constructs expressed 10- to
100-fold less protein than A3 plasmids expressed from the same vector as shown for A4-HA
(3xHA-tag) in comparison with A3G-HA (1xHA-tag) and A3A-HA (3xHA-tag) (Fig 2B). To
study the subcellular localization of the differently tagged A4 proteins, we analyzed the expres-
sion of these proteins in transfected HeLa cells using confocal microscopy. HA-A4 was local-
ized in both cytoplasm and nucleus (Fig 3A and 3B). A4-HA exhibited a predominantly
cytoplasmic distribution (Fig 3C and 3D). Untagged A4 could not be detected, because there
was no A4-specific antibody available. To analyze if the characteristic polylysine stretch
(KKKKKGKK) at the C-terminus is important for nuclear localization of A4, an N-terminal
HA-tagged mutant lacking the polylysine domain (HA-A4ΔKK, Fig 2A) was tested. Only few
cells showed expression of this protein, however, if expressed, HA-A4ΔKK was detectable in
nucleus and cytoplasm, suggesting that the polylysine stretch does not function as a nuclear
localization motif (Fig 3F).
A4 expression results in an increased HIV-1 particle yield
To determine the effect of A4 on HIV-1 particle production, we co-transfected increasing
amounts of the HA-A4 expression plasmid with a constant amount of HIV-1 expression
Fig 1. Differential expression of A4. (a) A4 expression was determined by semi-quantitative RT-PCR. Low
level A4 amplification by PCR using equal amount of cDNA prepared from total RNA of 293T, A3.01, Hela,
and Jurkat cell lines. As a control, β-2-microglobulin (ß-2-M) cDNA was amplified. Water instead of template
served as a background control and a plasmid coding for A4 cDNA (pA4 cDNA) served as a positive control.
M: 50 bp DNA ladder. (b) Levels of A4 expression were determined by quantitative real-time RT-PCR and
measured relative to endogenous HPRT1 RNA levels. A4 is expressed at a high level in human testis tissue,
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plasmid (pNL4-3 [56]). The total amount of transfected DNA was kept constant by replacing
HA-A4 with the empty expression plasmid (pcDNA3.1zeo). Two days post transfection, we
quantified virus production by measuring viral reverse transcriptase (RT) activity in the cell
culture supernatant (Fig 4A) and tested the cell lysate for expression of HIV-1 Gag (p24) by
immunoblot analysis (Fig 4B). Transfection of incremental amounts of HA-A4 plasmid caused
a 2.5-fold increase in the amount of released viral particles as reflected by the RT activity
detected in cell culture supernatants. Immunoblot analyses of viral lysates concentrated from
the cell culture supernatant also demonstrated the A4 stimulating effect on virus expression
(Fig 4B). This positive effect of HA-A4 on late stage HIV-1 particle production was highly
reproducible, as demonstrated by data from four independent experiments (Fig 4C). These
results were consistent with experimental findings using untagged A4 protein (data not
shown).
Production but not infectivity of HIV-1-luciferase is enhanced by A4
expression
We used VSV-G pseudotyped HIV-1 luciferase virus (NL.Luc R-E- [57]) to test whether
increasing the levels of expressed A4 influences HIV-1 production and infectivity. Co-transfec-
tion of A4 expression plasmids (data are shown for A4 and A4-HA plasmids in Fig 5A) and
NL-Luc resulted in a dose-dependent increase of intracellular virus-encoded luciferase activity
in transfected 293T cells. Presence or absence of the viral Vif protein (using the vif-deficient
NL.Luc R-E-Δvif/VSV-G in the same set of experiments) had no detectable effect on the
A4-induced stimulation of NL.Luc (data not shown). Immunoblot analysis of lysates isolated
from the transfected cells confirmed the A4 dose-dependent expression of viral capsid p24 (Fig
5B). Fig 5C shows that co-expression of HA-A4 with NL.Luc also caused a similar boost of Gag
expression, indicating that the location of the HA tag did not influence virus production
enhancement by A4. Results from 28, 16, and seven independent experiments using different
amounts of the A4-HA plasmid together with NL.Luc are summarized in Fig 5D, 5E and 5F,
respectively. These results confirmed a significant increase in NL-Luc-mediated luciferase
Fig 2. Expression of the A4-HA fusion proteins. (a) Schematic representation of protein domains and motifs found in the human A4 protein and tested
variants. Zn2+: presumed zinc-binding domain. HA (white boxes): HA-tag. KKKKKGKK: polylysine domain. (b) Increasing amounts of A4-HA (3xHA-tags),
A3G-HA (1xHA-tag) and A3A-HA (3xHA-tags) expression plasmids were transfected into 293T cells followed by immunoblot analysis of the transfected
cells using an anti-HA antibody. Immunoblot analysis with anti-tubulin (tub) antibody served as loading control. α, anti.
doi:10.1371/journal.pone.0155422.g002
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activity in the transfected virus producer cells (Fig 5D). When testing equal volumes of cell cul-
ture supernatants for the presence of infectious HIV reporter virions, we also detected a dose-
dependent increase in luciferase activity in infected cells (Fig 5E). However, when equal con-
centrations of viral particles normalized for RT activity were used escalating levels of A4-HA
did not cause a significant increase in infectivity (Fig 5F). The summarized individual experi-
ments did not always cover all ranges of applied plasmid concentrations (Fig 5D), and single
virus samples obtained from a subset of experiments were used to study particle infectivity (Fig
5E and 5F). Taken together, these data indicate that A4 expression enhances the production of
HIV-1, but does not change its infectivity.
Stable A4 expression enhances multiple-cycle replication of HIV-1
To test whether A4 can also enhance production of CCR5-tropic HIV-1, we co-transfected the
replication competent HIV-1 NL-BaL plasmid [58] with A4 expression plasmid and measured
the infectivity of RT value normalized particles using the HIV-reporter cell line TZM-bl [59].
Fig 3. Subcellular localization of A4 in transfected cells. Immunofluorescence confocal laser scanning microscopy
images of HeLa cells transfected with N- or C-terminal HA-tagged A4 (HA-A4 and A4-HA). (a, b) HA-A4 proteins show
cytoplasmic and nuclear localization. (c, d) A4-HA proteins show cytoplasmic localization. (a, c, e, f) x-y optical sections.
(b, d) x-z vertical scanning image of indicated cells (see asterisks). (e) Mock transfected cells (no A4). (f) HA-A4ΔKK
transfected cells show cytoplasmic and nuclear localization. To detect A4 (green) immunofluorescence, cells were stained
with an anti-HA antibody. Nuclei (blue) were visualized by DAPI staining. α, anti.
doi:10.1371/journal.pone.0155422.g003
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The expression of A4-HA resulted in enhanced expression of NL-BaL, as demonstrated by
immunoblots probed for viral capsid p24 and Vif proteins (Fig 6A). The viral particles har-
vested from this experiment demonstrated similar infectivity after normalization for RT activ-
ity (Fig 6B).
To analyze whether A4 expression can also enhance spreading replication of HIV-1, we gen-
erated a stable A4-HA expressing cell line derived from HOS.CD4.CCR5 cells [60] using a
G418-selectable retroviral A4-expressing vector (Fig 7A). As a control, we generated HOS.
CD4.CCR5.neo cells transduced with a retroviral vector just encoding the G418-resistance
Fig 4. A4 enhances the expression of HIV-1. (a) HIV-1 genome expression plasmid was co-transfected
with increasing amounts of HA-A4 expression plasmid, as indicated. A4 increases the production of HIV-1
particles as measured by the RT activity in the supernatant of the transfected cells. (b) Immunoblot analysis
of virions and transfected 293T cells (same cells as in (a)). Immunoblots of virions and cell lysates were
probed with anti-p24 (capsid) antibody. Anti-tubulin (tub) antibody served as loading control. α, anti. (c) RT
concentrations in the supernatant of cells co-transfected with HA-A4 and HIV-1 plasmids relative to
supernatant of cells co-transfected with empty vector and HIV-1, as in (a), summary of four independent
experiments, median indicated. Evaluation of RT activity data was performed by means of a multifactorial
analysis of variance (ANOVA).
doi:10.1371/journal.pone.0155422.g004
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gene. The cell lines were infected with NL-BaL, and virus spread was monitored for 20 days
(Fig 7B). HIV-1 showed comparable overall virus replication kinetics in both cell lines; how-
ever, HIV-1 replicated in the A4 expressing cells more efficiently resulting in 2–3 fold increased
virus titers. These data are consistent with our finding that A4 stimulated HIV expression in
Fig 5. Presence of A4 does not affect HIV-1 infectivity. HIV-1 reporter virus NL-Luc R-E- (VSV-G) was produced in 293T
cells in the presence of increasing amounts of A4 (no tag) and A4-HA (C-terminal HA-tag). A4 and A4-HA increase in a dose-
dependent manner both (a) the virus-encoded luciferase activity and (b) the expression of intracellular viral capsid (p24) in the
transfected virus producing cells as demonstrated by immunoblot analysis (same cell lysates used in (a) and (b)). Error bars
indicate standard deviation. (c) Immunoblot analysis of intracellular viral p24 (capsid) expression. Similar as in (a) and (b),
NL-Luc R-E-/VSV-G was co-transfected with increasing amounts of HA-A4 plasmid (N-terminal HA-tag), as indicated.
Immunoblots of cells were probed with anti-p24 (capsid) antibody. A4-HA expression in transfected cells was detected by
immunoblotting using anti-HA antibody. Anti-tubulin (tub) antibody served as loading control. α, anti. (d) Relative viral luciferase
activity in cells co-transfected with A4-HA and HIV-1 plasmids, as in (a). Summary of 28 independent experiments, median
indicated. A4-HA was transfected in increasing amounts. (e) Equal volumes of supernatants of cells co-transfected with NL-Luc
R-E-/VSV-G and increasing amounts of A4-HA were used to infect HOS cells. Intracellular luciferase activities were determined
in infected cells; summary of 16 experiments (a subset of the experiments shown in (d)), median is indicated. (f) A subset of
samples (seven experiments) used in (e) was quantified for RT concentrations. RT normalized supernatants of cells co-
transfected with NL-Luc R-E-/VSV-G and increasing amounts of A4-HA were used to infect HOS cells. Intracellular luciferase
activities determined in infected cells, median is indicated. (d—f) Statistical evaluation of reporter luciferase activity data was
performed by means of a multifactorial ANOVA.
doi:10.1371/journal.pone.0155422.g005
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the transient transfection experiments, supporting the premise that A4 modulates HIV-1
replication.
HIV enhancement is not mediated by cytidine deamination
To test whether cytidine deamination activity is associated with the described A4 effect, we
generated the active site mutants E95Q and C134A, in which the zinc-coordinating motif
HxEx30PCx6C (E95 and C134 underlined, x can be any amino acid) was mutated (Fig 2A).
Unexpectedly, only the A4-E95Q construct expressed detectable protein, precluding
A4-C134A mutant from functional studies (Fig 8A). To analyze if the active site mutation has
Fig 6. A4 enhances expression of CCR5-tropic HIV-1. (a) Increasing amounts of A4-HA expression plasmid were co-transfected with HIV-
1 NL-BaL and immunoblot analysis of co-transfected 293T cells were performed. Immunoblots were probed with anti-p24 (capsid), anti-Vif,
anti-HA and anti-tubulin (tub) antibodies. α, anti. (b) Infectivity of RT-normalized viral supernatant of the transfected cells from (a) were used
to infect TZM-bl luciferase reporter cells. cps, counts per second. Data are represented as the mean with SD. Statistically significant
differences between no A4 and A4 groups were analyzed using the unpaired Student’s t-test with GraphPad Prism version 5 (GraphPad
software, San Diego, CA, USA). Validity of the null hypothesis was verified with significance level at α value = 0.05. NS: not significant.
doi:10.1371/journal.pone.0155422.g006
Fig 7. A4 enhancesmultiple cycle replication of HIV-1. (a) Immunoblot analysis of A4-HA expressing HOS.CD4.CCR5.A4 cells (1) and empty
retroviral vector just encoding G418-resistance containing HOS.CD4.CCR5.neo cells (2) using an anti-HA antibody. Cell lysates were also
analyzed for equal amounts of total proteins by using anti-tubulin antibody. (b) HOS.CD4.CCR5.A4 and HOS.CD4.CCR5.neo cells were infected
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any effect on virus production, HIV-1 luciferase plasmid (NL.Luc R-E-) was co-transfected
with increasing amounts of A4-HA.E95Q expression plasmid and luciferase activity was mea-
sured in virus producer cells (Fig 8B). 293T cells showed higher virus-encoded luciferase activ-
ity after transfection of A4-HA.E95Q in a dose-dependent manner, comparable with the
luciferase enhancement after transfection of wildtype A4 (Fig 5A), indicating that cytidine
deamination activity of A4 protein is dispensable for the described HIV enhancing effect.
A4 lacks detectable cytidine deaminase activity
To evaluate the cytidine deaminase activity of A4 directly, we performed in vitro cytidine
deamination assays as described before [61, 62]. We expressed and purified GST-tagged fusion
proteins (GST-A3C, GST-A4, GST-A4ΔKK and free GST) from E. coli (Fig 9) and used them
for activity assays (Fig 10) and DNA binding experiments (Fig 11). In parallel, A3G-His was
purified from transfected 293T cells [62] (Fig 9) and used as a positive control for deamination
of CCC to CCU. Because the target preference for A4 is not known, we used two different oli-
gonucleotide substrates containing either CCCA/G or TTCA in the central region. If deamina-
tion of cytidine to uridine occurred, a 40-nt DNA product is generated after restriction enzyme
cleavage and detectable after separation of the digested substrate on a polyacrylamide gel. This
method demonstrated cytidine deamination of CCC oligonucleotide substrates by A3G-His
protein but not by GST-A4 (Fig 10A and 10B). Since E. coli-derived GST-proteins might not be
optimally folded and may differ in deamination activity or DNA binding due to the GST-tag,
we additionally tested APOBEC proteins encapsidated in virions, protein lysates of transfected
293T cells or APOBEC proteins immunoprecipitated from transfected cells (Fig 10C and 10E)
for their deamination activity (Fig 10D and 10F). We performed in vitro editing experiments
with HA-tagged A4, A4-ΔKK, A3F and A3G. In contrast to A3 proteins, A4 were not detected
in HIV-1 particles (Fig 10C). Similarly, only minor amounts of 3xHA-A4 were detectable in
Fig 8. Active site mutation has no influence on A4 activity. (a) Protein expression of A4-HA, A4-HA.E95Q and A4-HA.
C134A detected by anti-HA immuno blot analysis, showing equal amounts of A4-HA and A4-HA.E95Q, but lack of A4-HA.
C134A expression in transfected cells. (b) HIV-1 reporter virus (NL-Luc R-E-) was co-transfected with increasing amounts of
expression plasmid for A4-HA.E95Q. Virus encoded luciferase activity in the transfected cells was enhanced by A4-HA.E95Q
in a dose-dependent manner.
doi:10.1371/journal.pone.0155422.g008
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lysate of transfected 293T cells, but this could be enhanced by immunoprecipitation with HA
affinity beads (Fig 10E). We saw deamination of CCC to CCU and TTC to TTU only by A3G
and A3F, respectively. A4 did not deaminate in any of the above experiments irrespective of its
protein source, tags or target DNA (Fig 10D and 10F).
A4 weakly interacts with single stranded DNA
For A3 proteins such as A3G, interaction with single-stranded DNA (ss-DNA) and the forma-
tion of multiple DNA-protein complexes was shown [61, 63, 64]. We purified GST, GST-A4
and as a control, GST-A3C from E. coli to characterize whether GST-A4 interacts with ss-
DNA. Electrophoretic mobility shift assays (EMSA) were carried out with a biotinylated end-
labelled 30 nt DNA oligo (TTCA). GST as a background control protein did not cause any
characteristic shift. GST-A3C formed complex I, but a greater proportion shifted on the top of
the blot (complex II) at the highest protein concentration (1 μM) (Fig 11A). However, the addi-
tion of detergent NP-40 aided to form the stable complex I at 10 nM GST-A3C and complex II
at higher protein concentrations, suggesting a strong GST-A3C interaction with DNA. Impor-
tantly, the GST moiety did not affect the binding (Fig 11A). GST-A4 did not cause a shift at
low protein concentration like A3C or A3G [64], but at the highest amount of protein used
(500–1000 nM) a minor proportion of complex I was formed. All the DNA-protein complexes
in the EMSA were disrupted by adding the 80 nt unlabeled competitive DNA in 200-fold
molar excess. In contrast, GST-A4ΔKK failed to form any complexes (Fig 11B).
Crosslinking DNA-A3G studies previously showed that the deamination activity on ss-
DNA was facilitated when A3G formed dimers and tetramers [65]. These observations sug-
gested analyzing the capacity of A4 to form dimers. To demonstrate that A4 protein multi-
merizes in human cells, cleared cell lysate was incubated with different concentrations of the
cross linking reagent disuccinimidyl suberate (DSS). Immunoblot analysis of cross-linked sam-
ples dose-dependently revealed the existence of A4 running at the molecular weight expected
for dimers, indicating that primary amines which can be crosslinked with DSS are present
within the A4 dimerization interface (Fig 11C).
A4 enhances expression of HIV-1 LTR and other promoters
To test whether A4 enhances specifically HIV-1 production, we performed comparative
expression analysis of HIV-1 LTR and other viral and cellular promoters with and without A4
Fig 9. Recombinantly produced and affinity purified E. coli-derived GST, GST-A3C, GST-A4, GST-A4-
ΔKK proteins and 293T cell-derived A3G-His protein were resolved on a 10% SDS gel. Purity of the
proteins was determined by staining the gel with Coomassie blue. GST-A4, A3G-His and GST proteins are
indicated according to their molecular mass.
doi:10.1371/journal.pone.0155422.g009
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in the same cell. To this end, we co-transfected the NL-Luc plasmid expressing the firefly lucif-
erase gene which is located in the nef gene together with the Herpes simplex virus (HSV) thy-
midine kinase (TK) promoter-driven Renilla luciferase (HSV-RLuc) reporter plasmid and
different amounts of A4-HA expression plasmids. Both luciferases were measured sequentially
from single samples. The results revealed an A4 dose-dependent increase in both luciferase
activities (up to 2.5-fold for NL-Luc expression and up to 1.5-fold for the HSV driven lucifer-
ase) (Fig 12A). To test whether A4 affects HIV expression by acting on the viral LTR, luciferase
reporter constructs with the HIV-1 LTR (LTR-Luc, firefly luciferase) and HSV-RLuc were co-
Fig 10. A4 does not deaminate single stranded DNA. (a) Deamination activity of A4 was tested on two different oligonucleotide substrates
containing nucleotide sequences CCCA or CCCG. The A3G-His fusion protein was incubated with CCCA and CCCG containing substrates
and served as positive control for deamination resulting in 40-bp DNA fragments. Oligonucleotide CCUA served as a marker to denote the
deaminated product after Eco147I cleavage; ND: not deaminated; D: deaminated. (b) Deamination experiment using TTCA containing
oligonucleotide and GST-purified A4 proteins, RNAse A treatment was included; ND: not deaminated; D: deaminated. (c) Immuno blot
analysis of cell lysates and virus lysate of A3G-HA, A3F-HA, 3xHA-A4 and HA-A4-ΔKK expressing cells and HIV virus like particles (VLP),
respectively. Anti-HA staining indicates the presence of HA-tagged A3 and A4 proteins, while anti-p24 antibody detects HIV-1 capsid proteins.
(d) Deamination assay using transfected 293T cell lysate (from experiment shown in (c)). RNAse A treatment was included; ND: not
deaminated; D: deaminated. (e) Immuno blot analysis of cell lysate and immunoprecipitate (IP) fraction of A3 and A4 proteins. (f) Deamination
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transfected with increasing amounts of A4-HA expression plasmid with or without addition of
an HIV-1 Tat expression plasmid. As expected, the presence of Tat enhanced the expression of
the LTR-Luc construct (by 19-fold) relative to LTR-Luc expression in the absence of the Tat plas-
mid (Fig 12B). A4 expression in the absence of Tat stimulated the LTR-Luc expression by up to
2.6-fold and by up to 1.6-fold in the presence of Tat. The thymidine kinase promoter of HSV was
not sensitive to the presence of Tat. In contrast, A4 enhanced the HSV-RLuc expression by up to
2.8-fold when Tat was not co-transfected. In the next experiment, we tested firefly luciferase
expression constructs driven by promoters of HSV-TK, LINE1 (P850 L1), probasin, or prostate-
specific antigen (PSA), together with NL-Luc. Co-transfection with 2 μg A4-HA expression plas-
mid enhanced the luciferase activity of all these constructs from 3.5-fold to 5-fold, whereas
HIV-LTR expression was enhanced by 7-fold (Fig 12C). Based on these results, we conclude that
A4 might directly or indirectly enhance the transcription of HIV and other promoters.
Discussion
Herein we report the first study addressing the potential function of the A4 protein in human
cells. A4 is the most recently identified and the least studied APOBEC protein [3, 52]. It is
more closely related to A1 than to the A3 proteins [3]. Knowledge about the A4 protein is very
limited; it is unknown if A4 binds to RNA or DNA or possesses any enzymatic activity, and no
biochemical and structural information about A4 is available to date. Our data show for the
first time biological activity of A4, which enhances the expression of HIV-1.
As part of this study, we established mammalian expression plasmids for A4 and we also
generated bacterially expressed GST-A4 fusion proteins to test for their enzymatic activity.
Under experimental conditions that readily detect cytidine deamination by A3G, purified
GST-A4 did not carry out any detectable cytidine deamination. We also tested A4 isolated
from transfected human cells and similarly found no cytidine deamination activity. These find-
ings are in agreement with the previously reported absence of cytidine deamination of A4
using a cellular mutation assay in bacteria and yeast [52]. In addition, we found that mutating
Fig 11. A4 interacts weakly with single-stranded DNA. EMSA with purified, GST-A3C (a), GST-A4 and GST-A4ΔKK (b) performed with 30 nt single
stranded target DNA labeled with 3’-labeled with biotin. Indicated amounts of protein (at the bottom of blot) were titrated with 10 nM of DNA. (+) indicates
presence of competitor DNA, which is unlabeled 80 nt DNA (200-fold molar excess), as used for deamination assay to demonstrate specific binding of
protein to DNA being causative for the shift. For GST-A3C (a) a separate panel was added for reactions containing 0.05% NP-40 detergent. (c) A4-HA
crosslinking by DSS. DSS was added to the cleared cell lysates to reach the indicated DSS concentrations. The blot was probed with anti HA antibody to
detect monomeric and dimeric forms of A4-HA.
doi:10.1371/journal.pone.0155422.g011
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the zinc-coordinating domain of A4 did not abolish the HIV-enhancing activity of A4. Never-
theless, these observations do not mean that A4 is catalytically inactive, A4 may just have dif-
ferent substrate specificity and cytidine deamination may not be the A4 function required for
enhancement of HIV expression.
The deamination activity of A3 proteins such as A3G on ss-DNA is facilitated by A3G
dimers and tetramers [65]. A4 formed at least dimers, but did weakly bind to ss-DNA only.
This weak DNA binding was lost, if the characteristic polylysine stretch (KKKKKGKK) at the
C-terminus of A4 was deleted (A4ΔKK), supporting the hypothesis that the net positive charge
rendered by polylysines confer some capacity to interact with DNA [66]. Thus, the weak inter-
action of A4 with ss-DNA may be one reason for the lack of detectable deamination.
We speculated that the polylysine domain would be involved in nuclear localization of A4
and that a C-terminal HA-tag would obstruct this activity, because A4 with an N-terminal
Fig 12. A4 enhances expression of luciferase reporter genes driven by various viral and cellular promoters. (a) Dual
luciferase reporter assay was performed two days post co-transfection of NL-Luc R-E- and HSV-TK promoter Renilla luciferase
(HSV-RLuc) with and without A4-HA, relative luciferase activities are shown. (0) indicates transfections in the absence of
A4-HA plasmid. A4-HA was transfected in increasing amounts. (b) Relative luciferase activities after co-transfection of
LTR-Luc (LTR of HIV-1 driving firefly luciferase) with A4-HA or HSV-TK promoter Renilla luciferase (HSV-RLuc) with A4-HA
and with and without Tat expression plasmid (c) Luciferase activities driven by various viral (LTR, HSV TK) or cellular
promoters (LINE, Probasin, PSA) in presence of the transfected A4-HA expression plasmid, relative to luciferase activity in
cells without A4 expression. Total amounts of luciferase expression plasmid and total plasmid DNA was kept constant within
all experiments. Error bars indicate standard deviation.
doi:10.1371/journal.pone.0155422.g012
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HA-tag (HA-A4) localized to both cytoplasm and nucleus of transfected cells, while A4-HA
with a C-terminal HA-tag was detected only in the cytoplasm. However, HA-A4ΔKK also
localized to both compartments, cytoplasm and nucleus, suggesting that the polylysine domain
is not important for nuclear localization. C-terminal stretches of lysines are also found in
other proteins unrelated to A4 e.g. in the GTPase KRas (KRAS, K-Ras4B, NP_004976) and
FAM133B (NP_001035146). In KRas, the polylysine region (KKKKKKSK) contributes to the
interaction of KRas with Ca2+/calmodulin and strongly influences its binding to the plasma
membrane by electrostatic interactions with the membrane anionic lipids [67, 68]. Whether A4
specifically interacts with membranes or Ca2+/calmodulin is not known.
We demonstrated that A4 mRNA is highly expressed in human testis, but is barely detect-
able in 293T, HeLa, A3.01 T and Jurkat T cell lines. Analysis of protein expression of endoge-
nous A4 was precluded, due to the non-availability of any A4-specific antibody. In light of the
sexual transmission of HIV-1 and the possibility of sanctuary sites for HIV-1 in the male geni-
tal tract, the origin of seminal HIV-1 is a topic of ongoing discussion [69–76]. Human testicu-
lar tissue is described to be susceptible to HIV-1 [69, 72, 77–80] and macaque testis and
epididymis are found to be infected by SIV in several studies [70, 73, 76, 81, 82]. Since we do
not know whether CD4+ cells in testis express A4, we cannot make a statement concerning
modulation of HIV infection in testis by A4. A4 also enhanced the expression of firefly lucifer-
ase which is controlled by the HIV-1 LTR in a manner similar to that of the unrelated HSV
promoter driven Renilla luciferase and A4 expression increased the expression of luciferase
constructs driven by cellular promoters. However, our results do not clearly demonstrate that
A4 is a factor that enhances LTR-mediated transcription. Indeed, it is thus likely that HIV ben-
efits from a broad activity of A4. We hypothesize that A4 creates a cellular/nuclear environ-
ment that stimulates for example the expression of HIV-1. A4 may boost expression or activity
of a factor important for HIV or reduce the expression or activity of a negative regulator of
HIV. It is very well possible that the observed enhancing activity of A4 to HIV is relevant for
the expression of cellular promotors and endogenous retroviruses in testis [83]. Future studies




pA4-HA (pA4-3xHA) expresses APOBEC4 (A4, GenBank NM_203454.2) fused to three
C-terminal HA-tags; pMH-A4_3xHA (obtained fromMatthias Hamdorf) was used to excise
A4-3xHA using EcoRI x NotI, cloned into EcoRI / NotI of pcDNA3.1zeo(+) (Life Technolo-
gies, Darmstadt, Germany). pA4-HA-E95Q was generated by side-directed mutagenesis of the
pA4-HA plasmid, the mutation was confirmed by sequencing. pA4 expresses A4 without an
epitope tag. pA4 was cloned by PCR (pA4-HA as template) using primers hA4 5’ (5’-CGGAT
CCCTAGCAATGGAGCCCATATATG) and hA4 3’ (5’-GAATTCTTTATTTCTTCCCTTTC
TTCTTCTTC), the PCR product was cloned via BamHI / EcoRI into pcDNA3.1zeo(+). HA-
A4 (p2xHA-A4): expresses A4 with two N-terminal HA-tags, a pcDNA3.1zeo(+)-based plas-
mid with one N-terminal HA-tag of A4 was generated by PCR using primers HA-hA4 5’
(5’-CGGATCCCTAGCAATGGGATATCCATACGATGTTCCAGATTACGCTGAGCCCA
TATATGAGGAGTACC) and hA4 3’ (5’-GAATTCTTTATTTCTTCCCTTTCTTCTTCTTC);
this plasmid served as template for a second PCR using primers for_2xHA-A4 (5’-CGGGATC
CCTAGCAATGGGATATCCATACGATGTTCCAGATTACGCTGGCTATCCATACGATG
TTCCAGATTACGCTGGCTATCCATACGATGTTCCAGATTACGCT) and rev rc_hA4
(5’-GCCGGAATTCTTATTTCTTCCCTTTCTTCTTCTTC). The product was cloned via
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BamHI / EcoRI into pcDNA3.1zeo(+). pGST-A4: A4 with an N-terminal GST-tag in pGEX-
6-P1 (GE Healthcare, Munich, Germany), A4 was cloned via BamHI / EcoRI by excising A4
from pA4. Similarly pGST-A4-ΔKK was cloned in pGEX-6-P1 (GE Healthcare, Freiburg, Ger-
many) using forward primer 5’- ATCGGATCCATGGAGCCCATATATGAGGAG and
reverse primer 5’-CGGCGAATTCTTATTCATCTGCCTCCTTGCTACT. pMSCV.A4: a
murine leukemia virus-based vector to express A4 fused with three C-terminal HA-tags; it was
cloned by PCR using template pA4-3xHA and primers A4_fw_RI (5’-TGGAATTCGCCCTT
CAGGCGGTACCAGCCTGGAGACAAATTGATG) and A4_rv_RI (5’-TAGAATTCTCAGT
TAGCCGGCGTAG)via EcoRI into pMSCV.neo (Clonetech, Takara Bio Europe/SAS, Saint-
Germain-en-Laye, France). pLTR-Luc (pGL3-bas-NL43LTR-luc): containing the LTR region
of HIV-1 pNL4-3, cloned by PCR of U3, R, and TAR elements using primers NL4-3-U3(+)
(5´-CTCGGCAGATCTCTGGAAGGGCTAATTCACTCC) and U3/R/TAR(-) (5´-GCTCGG
AAGCTTGGCTTAAGCAGTGGGTTCCCTAG); amplicons were cloned via HindIII and
BglII (partial digest) into pGL3-Basic (Promega, Mannheim, Germany). P850 luciferase plas-
mid with LINE Promotor (P850 L1) [84] and reporter constructs with androgen responsive
promotors probasin (pGL3Eprob) and PSA (pPSA61-luc) [85] were kindly provided by Wolf-
gang A. Schulz. APOBEC3G (A3G)-HA expression construct was kindly provided by Natha-
niel R. Landau [17]. His-tagged huA3G (A3G-Myc-6His) has been described previously [86].
APOBEC3A (A3A)-HA expression plasmid was obtained from Bryan R. Cullen [87]. pTat
(pBS-KRSPA-Tat NL4-3), expressing Tat protein of HIV-1 NL4-3 was a gift of Heide Mucken-
fuss and Egbert Flory. For cloning of pTat, both Tat exons were amplified and fused by PCR
using pNL4-3 [56] as template, and cloned into XhoI / SpeI of pBS-kRSPA [88]. pHSV-RLuc
(pRG-TK, Promega), Renilla reniformes luciferase expressed by the Herpes simplex virus type 1
thymidine kinase promoter.
Cells, transfections and infections
HOS (ATCC CRL-1543), HOS.CD4.CCR5 [60], HeLa (ATCC CCL-2), TZM-bl [59] and 293T
(ATCC CRL-3216) cells, were maintained in Dulbecco’s modified Eagle’s medium complete
(PAN-Biotech, Aidenbach, Germany); A3.01 T cells [89] and Jurkat T cells clone E61 (ATCC
TIB152) were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (PAN-Bio-
tech) supplemented with 10% FBS, 0.29 mg/ml L-glutamine, and 100 U/ml penicillin/strepto-
mycin at 37°C in a humidified atmosphere of 5% CO2. Plasmid transfections into 293T cells
were performed with Lipofectamine LTX (Life technologies). HIV-1 and reporter lentiviruses
were generated by transfection in 6-well plates with 200 ng pNL.Luc R- E- (pNL4-3.Luc.R–.E–)
[57] plus 50 ng vesicular stomatitis virus G glycoprotein (VSV-G) expression plasmid pMD.G
or with 1 μg pNL4-3 [56] and different amounts of A4 expression plasmid. Total transfected
plasmid DNA was maintained by adding appropriate amounts of pcDNA3.1zeo(+) plasmid
DNA where needed. To produce NL4.3 with the env BaL, pNL-BaL [58] was transfected in
293T cells. Reverse-transcriptase (RT) activity was determined using the Cavidi HS kit Lenti
RT (Cavidi Tech, Uppsala, Sweden). For infectivity assays, 4x103 HOS cells were transduced in
96-well plates in triplicate with a virus amount equivalent to 10 pg of RT for HIV. Three days
post infection, luciferase activity was measured using the Steadylite HTS kit (PerkinElmer,
Rodgau, Germany). To quantify firefly and Renilla luciferase in the same cell lysate, the dual-
Luciferase reporter assay (Promega) was applied. All luciferase assays in transfected cells were
performed two days post transfection. To generate stable A4-expressing HOS.CD4.CCR5.A4
and control HOS.CD4.CCR5.neo cells, pMSCV.A4 or pMSCV.neo plasmid was co-transfected
together with pHIT60 [90] and pMD.G for generation of murine leukemia viral vector parti-
cles. Vector particles were used to transduce HOS.CD4.CCR5 cells; G418 resistant cells were
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pooled and characterized for CD4 and CCR5 receptor and A4 expression. Spreading virus rep-
lication with NL-BaL was quantified over 20 days infecting HOS.CD4.CCR5.neo or HOS.CD4.
CCR5.A4 cells using a multiplicity of infection of 0.01 and testing the culture supernatants
with the HIV reporter cell line TZM-bl [59]. Transfection efficiency was monitored by cotrans-
fection of 100 ng Monster Green fluorescent protein expression plasmid hMGFP (Promega).
Immunoblot analysis
Cells were lysed in radioimmunoprecipitation assay buffer (RIPA, (25 mM Tris (pH 8.0), 137
mMNaCl, 1% glycerol, 0.1% SDS, 0.5% Na-deoxycholat, 1% Nonidet P-40, 2 mM EDTA, and
protease inhibitor cocktail set III [Calbiochem, Darmstadt, Germany].) buffer, 20 min on ice.
Lysates were clarified by centrifugation (10 min, 300 g, 4°C). Samples were boiled in NuPAGE
SDS Sample Buffer and NuPAGE Sample Reducing Agent (Life technologies) and subjected to
SDS-PAGE followed by transfer to a PVDF membrane. A3G and A4 Proteins were detected
using an anti-HA antibody (Ab) (1:104 dilution, MMS-101P; Covance, BioLegend, Fell, Ger-
many), HIV-1 p24 Gag was detected applying HIV-1 p24 monoclonal Ab (1:250 dilution,
AG3.0, NIH AIDS REAGENTS, Germantown, USA) [91]. Cell lysates were probed with α-
tubulin Ab (1:104 dilution, B5-1-2; Sigma-Aldrich, Munich, Germany) and virions with α-p24
monoclonal Ab 183-H12-5C. Vif protein was detected with HIV-1 Vif monoclonal antibody
(1:5x103 dilution, #319, NIH AIDS REAGENTS) [92]. Secondary Abs.: anti-mouse (NA931V)
and anti-rabbit (NA934V) horseradish peroxidase (1:104 dilution, GE Healthcare). Signals
were visualized using ECL reagent (GE Healthcare).
Chemical cross linking
293T cells were transfected with pA4-HA and lysed two days after transfection with RIPA
buffer. Soluble fraction was clarified by centrifugation at 13,000 rpm and 4°C. To chemically
cross link the amines of the protein, the lysate was treated with various concentrations of disuc-
cinimidyl suberate (DSS) (Thermo Scientific, Braunschweig, Germany) dissolved in DMSO to
make a final concentration of 50, 100 and 500 μM and the reaction mixture was incubated for
20 min on ice. To quench the reaction, 20 mM of Tris (final concentration) was added and
lysates were subjected to immunoblot analysis without addition of reducing reagent. The pres-
ence of A4 monomers and dimers were detected by anti HA antibody.
PCR
Total RNA was isolated using RNeasy mini kit (Qiagen, Hilden, Germany). Human testis RNA
(DNase free, HR-401) was obtained from Zyagen (San Diego, USA). RNA was reverse tran-
scribed with QuantiTect Reverse Transcription (Qiagen). Semi-quantitative PCR analyses of
A4 mRNA: The A4 fragments were amplified from cDNA by Dream-Taq polymerase (Thermo
Scientific) and the primers Origene_for (5‘-CAAGCCTGGAGACAAATTGATGG) x Origen-
e_rev (5‘-GCAATCGAGAGAGAAGCTTAGCC). As a control, β-2-microglobulin cDNA was
amplified in the same PCR reaction applying primer β-2-Mikroglobulin A_for (5’-CTCGCTC
CGTGGCCTTAGCTGTGCTCGCGC) x β-2-Mikroglobulin A_rev (5’-TAACTTATGCACG
CTTAACTATC): Initial denaturation at 95°C for 5 min followed by 39 cycles of 95°C for 1
min, 56°C for 1 min, 72°C for 1 min and final extension 72°C for 15 min. Water instead of
template served as a background control and a plasmid coding for A4 cDNA (pA4 cDNA)
served as a positive control. The identity of the PCR fragments was confirmed by cloning and
sequencing. Quantitative real-time PCR analyses of A4 mRNA: The A4 fragments were ampli-
fied from cDNA using SYBR green PCRMaster Mix (Applied Biosystems, Warrington, United
Kingdom) with an Applied Biosystems 7500 Real-Time PCR system (Applied Biosystems,
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Foster City, CA) and primers: A4_909_for (5’-ACCAATGCATATGGGCCAAA) x A4_906_
rev rc (5’-GTGCCTTACGATATTCCTGGGT). After initial incubations at 50°C for 2 min and
95°C for 10 min, 40 cycles of amplification were carried out for 15 s at 95°C, followed by 1 min
at 60°C. The amplification product was normalized to that of HPRT1 using PCR Primers
HPRT1_for (5’-GCTTTCCTTGGTCAGGCAGT) x HPRT1_rev rc (5’-GCTTGCGACCTTGA
CCATCT).
Purification of A3 and A4 proteins from E. coli and 293T cells
A3G-His was expressed in 293T cells and purified by immobilized metal affinity chromatogra-
phy (IMAC) using Ni-nitrilotriacetic acid (Ni-NTA) agarose (Life Technologies) as described
[62]. GST-A3C, GST-A4, GST-A4ΔKK and GST proteins were overexpressed in E. coli Rosetta
(DE3) cells (Millipore, Merck Chemicals, Darmstadt, Germany) and purified by affinity chro-
matography using Glutathione Sepharose 4B beads (GE healthcare). After the growth of trans-
formants containing pGEX4T2-GST-A4 until 0.6 OD600, cells were induced with 1 mM
isopropyl-beta-D-thiogalactopyranoside (IPTG) and 1 μMZnSO4 and cultured at 18°C over-
night. A4 harboring cells were washed with PBS and lysed with 1X Bug buster protein extrac-
tion reagent (Millipore) containing 50 mM Tris (pH 7.0), 10% glycerol, 1 M NaCl and 5 mM
2-mercaptoethanol (2-ME), clarified by centrifugation (14,800 rpm for 20 min at 4°C) and the
soluble fraction was mixed with glutathione sepharose beads. After 3 h incubation at 4°C in
end-over-end rotation, the beads were washed twice with wash buffer containing 50 mM Tris
(pH 8.0), 5 mM 2-ME, 10% glycerol and 500 mMNaCl. The bound GST-A4 protein was eluted
with wash buffer containing 20 mM reduced glutathione. Purified protein concentration was
determined spectrophotometrically by measuring the A280, using their (theoretical) extinction
coefficient and molecular mass.
In vitro DNA cytidine deamination assay
Deamination reactions were performed as described [61, 62] in a 10 μL reaction volume con-





GTGATGGAAGTTATGTTTGGTAGATTGATGG). Samples were splitted into two halves; in
one half 50 μg/ml RNAse A (Thermo Scientific) was added. Reactions were incubated for at
least 1 h at 37°C and the reaction was terminated by boiling at 95°C for 5 min. One fmol of the
reaction mixture was used for PCR amplification (Dream Taq polymerase (Thermo Scientific)
95°C for 3 min, followed by 19 cycles of 61°C for 30 sec and 94°C for 30 sec) and the primers
forward 5'-GGATTGGTTGGTTATTTGTTTAAGGA, reverse 5'-CCATCAATCTACCAAAC
ATAACTTCCA used to amplify CCC(A/G) substrate, forward primer 5’-GGATTGGTTGGT
TATTTGTATAAGGA with the above reverse primer used for TTCA. PCR products of CCC
(A/G) and TTCA were digested with Eco147I (StuI) (Thermo Scientific) and MseI (NEB,
Frankfurt/Main, Germany), respectively, resolved on 15% PAGE, stained with ethidium bro-
mide (5 μg/ml). As a positive control substrate oligonucleotides with CCUA and TTUA instead
of respective CCCA and TTCA were used to control the restriction enzyme digestion.
APOBEC incorporation into HIV-1: HIV-1 vectors were produced with 250 ng A3 plasmids
and 1000 ng A4 constructs. 48 h later virion containing supernatants were concentrated by lay-
ering on 20% sucrose cushion and centrifuged for 4 h at 14,800 rpm. Viral particles were re-
suspended in mild lysis buffer (50 mM Tris (pH 8), 1 mM PMSF, 10% glycerol, 0.8% NP-40,
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150 mMNaCl and 1X complete protease inhibitor) and used as input for the in vitro deamina-
tion assay.
Deamination assay using immunoprecipitated protein from 293T cells: 293T cells were
transfected with expression plasmids encoding A4-HA, 3xHA-A4, A3G-HA or A3F-HA. Cells
were lysed 48 h post transfection with mild lysis buffer (50 mM Tris (pH 8.0), 1 mM PMSF,
10% glycerol, 0.8% NP-40, 150 mMNaCl and protease inhibitor (protease inhibitor cocktail
set III, Calbiochem). HA-tagged proteins were immunoprecipitated using 20 μl of anti-HA
Affinity Matrix Beads (Roche Diagnostics, Mannheim, Germany) by slowly rotating the lysate
bead mixture for 2 h at 4°C. One third of the beads were used for deamination assay and the
remaining was used for immunoblot analysis.
Electrophoretic mobility shift assay (EMSA) with GST-A3C and GST-A4
EMSA method is adapted from [63, 64]. Proteins were produced as described above, kept in
protein buffer (final concentration 50 mM Tris (pH 8.0), 50 mM NaCl, and 10% glycerol). 10
mM 3’ biotinylated DNA (30-TTC-Bio-TEG purchased from Eurofins Genomics, Ebersberg
Germany) was mixed with 10 mM Tris (pH 7.5), 100 mM KCl, 10 mMMgCl2, 1 mM DTT, 2%
glycerol, and desired amount of recombinant proteins in a 10 μl reaction mixture, and incu-
bated at 25°C for 30 min. The protein-DNA complex was resolved on a 5% native PAGE gel on
ice, and then transferred onto nylon membrane (Amersham Hybond-XL, GE healthcare) by
southern blot. After transfer, the molecules on the membrane were crosslinked by UV-radia-
tion using a transilluminator at 312 nm for 15 min. Chemiluminescent detection of biotiny-
lated DNA was carried out according to the manufacturer’s instruction (Thermo scientific).
Confocal microscopy
1 x 105 HeLa cells grown on coverslips (Marienfeld, Lauda Königshofen, Germany) were trans-
fected with 500 ng A4 expression plasmids by applying Lipofectamine LTX transfection
reagent. At day two post transfection, cells were fixed in 4% paraformaldehyde in PBS for 30
min, permeabilized in 0.1% Triton X-100 in PBS for 45 min, incubated in blocking solution
(10% donkey antiserum (Sigma-Aldrich) in PBS) for 1 h, and treated with anti-HA Ab (MMS-
101P; Covance) in blocking solution for 1 h. Donkey anti-mouse Alexa Fluor 488 (Life Tech-
nologies) was used as secondary Ab in a 1:300 dilution in blocking solution for 1 h. Finally,
nuclei were stained using DAPI (4’, 6’-diamidino-2-phenylindole; 1:1000 in PBS) (Merck Milli-
pore, Darmstadt, Germany) for 5 min. Coverslips were mounted on glass microscope slide
(Marienfeld) using Fluorescent Mounting Medium (DAKO, Hamburg, Germany). The images
were captured by using a 63x objective on a Zeiss LSM 510 Meta laser scanning confocal micro-
scope. x-z optical sections were acquired from 0.28 μm layers.
Statistics
Evaluation of RT or reporter activity data was performed by means of a multifactorial analysis
of variance (ANOVA) with fixed factor plasmid ratio. Additionally a random factor day was
included, if more than one determination were obtained from one day in order to model day-
to-day variability. The statistical analysis was performed with SAS/STAT software, version 9.3,
SAS System for Windows (Cary, USA).
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